Gender-specific associations of the APOA1 -75G>A polymorphism with several metabolic syndrome components in Turkish adults

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 244-249

  Coban, Neslihan ^a   Onat, Altan ^a   Guclu Geyik, Filiz ^a   Komurcu Bayrak, Evrim ^a   Can, Gunay ^a   Erginel Unaltuna, Nihan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apolipoprotein A1; Atherogenic dyslipidemia; Blood pressure; HDL C; Polymorphism

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HUMAN; HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TURKISH; BLOOD; BLOOD PRESSURE; EPIDEMIOLOGY; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; TURKEY;

ADULT; APOLIPOPROTEIN A-I; BLOOD GLUCOSE; BLOOD PRESSURE; DYSLIPIDEMIAS; FEMALE; GENOTYPE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS; TURKEY;

EID: 84896048700     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.017     Document Type: Article

References (34)

1. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001, 285:2486-2497.
2. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., Buring J.E. Fasting triglycerides, high-density lipoprotein and the role of myocardial infarction. Circulation 1997, 96:2520-2525.
3. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003, 139:802-809.
4. Holleboom A.G., Vergeer M., Hovingh G.K., Kastelein J.J., Kuivenhoven J.A. The value of HDL genetics. Curr Opin Lipidol 2008, 19:385-394.
5. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
6. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991, 353:265-267.
7. Larson I.A., Ordovas J.M., Barnard J.R., et al. Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. Clin Genet 2002, 61:176-184.
8. Talmud P.J., Ye S., Humphries S.E. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis research study. Genet Epidemiol 1994, 11:265-280.
9. Jeenah M., Kessling A., Miller N., Humphries S.E. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990, 7:233-241.
10. Sigurdsson G.J., Gudnason V., Sigurdsson G., Humphries S.E. Interaction between a polymorphism of the apoA-I promoter region and smoking determines plasma levels of HDL and apoA-I. Arterioscler Thromb 1992, 12:1017-1022.
11. Wang X.L., Badenhop R.B., Sim A.S., Wilcken D.E. The effect on transcription efficiency of the apolipoprotein AI gene of DNA variants at the 5' untranslated region. Int J Clin Lab Res 1998, 28:235-241.
12. Pagani F., Sidoli A., Giudici G.A., Barenghi L., Vergani C., Baralle F.E. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 1990, 31:1371-1377.
13. Barre D.E., Guerra R., Verstraete R., Wang Z., Grundy S.M., Cohen J.C. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994, 35:1292-1296.
14. de Franca E., Alves J.G., Hutz M.H. APOA1/C3/A4 gene cluster variability and lipid levels in Brazilian children. Braz J Med Biol Res 2005, 38:535-541.
15. Xu C.F., Angelico F., Del Ben M., Humphries S.E. Role of genetic variation at the apoAI-CIII-AIV gene cluster in determining plasma apoA-I levels in boys and girls. Genet Epidemiol 1993, 10:113-122.
16. Morcillo S., Cardona F., Rojo-Martinez G., et al. Association between MspI polymorphism of the APO AI gene and type 2 diabetes mellitus. Diabet Med 2005, 22:782-788.
17. Block R., Corsetti J., Goldenberg I., et al. The common apolipoprotein A-1 polymorphism -75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction. Heart Int 2009, 30. 4:e8 [http://dx.doi.org/10.4081/hi.2009.e8].
18. Chen E.S., Mazzotti D.R., Furuya T.K., et al. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med 2009, 9:319-325.
19. Phillips C.M., Goumidi L., Bertrais S., et al. Gene-nutrient interactions and gender may modulate the association between ApoA1 and ApoB gene polymorphisms and metabolic syndrome risk. Atherosclerosis 2011, 214:408-414.
20. Sadaf A., Siddiqui S., Lestringant G.G., Frossard P.M. Apolipoprotein AI promoter variant in blood pressure determination. Clin Genet 2002, 61:314-316.
21. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001, 156:1-10.
22. Genuth S., Alberti K.G., Bennett P., et al. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
23. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
24. Onat A., Uyarel H., Hergenc G., Karabulut A., Albayrak S., Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007, 191:182-190.
25. Bai H., Saku K., Liu R., Jimi S., Arakawa K. Analysis of a new polymorphism in the human apolipoprotein A-I gene: association with serum lipoprotein levels and coronary heart disease. J Cardiol 1996, 28:207-212.
26. Wu J.H., Kao J.T., Wen M.S., Lo S.K. DNA polymorphisms at the apolipoprotein A1-CIII loci in Taiwanese: correlation of plasma APOCIII with triglyceride level and body mass index. J Formos Med Assoc 2000, 99:367-374.
27. Lahoz C., Pena R., Mostaza J.M., et al. Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 2003, 168:289-295.
28. Al-Yahyaee S.A., Al-Kindi M.N., Al-Bahrani A.I. Apolipoprotein A1 gene polymorphisms at the -75bp and +83/84bp polymorphic sites in healthy Omanis compared with world populations. Hum Biol 2004, 76:307-312.
29. Yin R.X., Li Y.Y., Lai C.Q. Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels. Lipids Health Dis 2011, 19:10-140. [http://www.lipidworld.com/content/10/1/140].
30. Ding Y., Zhu M.A., Wang Z.X., Zhu J., Feng J.B., Li D.S. Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome. J Biomed Biotechnol 2012, 10.1155/2012/509420.
31. Paul-Hayase H., Rosseneu M., Robinson D., Van-Bervliet J.P., Deslypere J.P., Humphries S.E. Polymorphisms in the apolipoprotein (apo) AICIII-AIV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum Genet 1992, 88:439-446.
32. Superko H.R. Lipoprotein subclasses and atherosclerosis. Front Biosci 2001, 6:355-365.
33. Jia L., Bai H., Fu M., Xu Y., Yang Y., Long S. Relationship between plasma HDL subclasses distribution and apoA-I gene polymorphisms. Clin Chim Acta 2005, 360:37-45.
34. Onat A., Örnek E., Çiçek G., Murat S.N., Can G. Increased apolipoprotein A-I levels mediate the development of prehypertension. Anadolu Kardiyol Derg 2013, 13:306-314.